
CG Oncology, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an oncolytic immunotherapy administered intravesically for the treatment of bladder cancer.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| POST LEONARD EDirector | Sell | $31K | 500at $61.65 | Oct 15, 2026 |
| POST LEONARD EDirector | Sell | $31K | 500at $62.48 | Oct 15, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CGON activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.